Parrondo, Ricardo D.
Rahman, Zaid Abdel
Heckman, Michael G.
Wieczorek, Mikolaj
Jiang, Liuyan http://orcid.org/0000-0002-9851-985X
Alkhateeb, Hassan B. http://orcid.org/0000-0002-3609-8404
Litzow, Mark R. http://orcid.org/0000-0002-9816-6302
Greipp, Patricia
Sher, Taimur
Bergsagel, Leif http://orcid.org/0000-0003-1523-7388
Fonseca, Rafael http://orcid.org/0000-0002-5938-3769
Roy, Vivek http://orcid.org/0000-0002-5950-4620
Dispenzieri, Angela http://orcid.org/0000-0001-8780-9512
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Murthy, Hemant S.
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Foran, James M. http://orcid.org/0000-0003-1673-1708
Article History
Received: 24 February 2022
Accepted: 9 May 2022
First Online: 1 June 2022
Competing interests
: Parrondo, Abdel Rahman, Jiang, Heckman, Wieczorek, Jiang, Alkhateeb, Greipp, Roy, Sher have no conflicts of interest to declare. Litzow: Research funding: AbbVie, Astellas, Amgen, Actinium, Pluristem, Advisory Board: Jazz, Omeros. Bergsagel: Consultancy: Janssen. Fonseca: Consultancy: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, GSK, OncoTracker. Board of Directors: Adaptive Biotechnologies, Caris Life sciences. Dispenzieri: Research Funding: Pfizer, Alnylam, Takeda, Janssen. Consultancy: Oncopeptides, Sorrento Therapeutic Ailawadhi: Celgene: Consultancy; Amgen: Consultancy, Research Funding; Pharmacyclics: Research Funding; Cellectar: Research Funding; Janssen: Consultancy, Research Funding; Takeda: Consultancy. Foran: Honoraria: Pfizer, Novartis, Servier, BMS, Revolution Medicine, Taiho, Syros, Sanofi Aventis, Certara, Gamida, OncLive, Research Funding: Abbvie, Boehringer Ingelheim, Takeda, Trillium, Aptose, Actinium, Kura, h3bioscience, Aprea, Sellas, Stemline.